RxDoctor Payments Data

Raktim Ghosh, MD

Cardiovascular Disease · Baltimore, MDNPI 1588004071

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Atricure, Inc. at 25.7% of the total. That places this record below the midpoint for cardiovascular disease clinicians in MD, where the typical reported total is $1,418.

$504in general payments, 2019–2025

Across 12 payments — averaging $41.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$129
  • Boston Scientific$124
  • Lantheus Medical Imaging, Inc.$111
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$58
  • Edwards Lifesciences$31
  • Philips North America LLC$27
  • plus $24 from 1 others
$26,488in research payments, 2019–2025

Across 31 payments — averaging $854.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Esperion Therapeutics, Inc.$21K
  • Kowa Research Institute, Inc.$5K

What the payments were for

  • Food & beverage$504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$504 in reported general payments places this provider in the 35th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland →

Medicare billing

Part B allowed, 2024
$471,386
Medicare patients
3,395
Services billed
8,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$208,717
EntrestoSacubitril/Valsartan106$155,365
JardianceEmpagliflozin67$92,263
XareltoRivaroxaban59$65,123
NexlizetBempedoic Acid/Ezetimibe37$32,943
Praluent PenAlirocumab19$10,923
VascepaIcosapent Ethyl13$9,221
Dofetilide13$5,866
Ranolazine ErRanolazine44$5,060
Metoprolol Succinate252$4,383
Ezetimibe64$4,290
Atorvastatin Calcium223$3,727
Rosuvastatin Calcium76$2,502
Carvedilol181$2,032
Nitroglycerin91$1,987

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Baltimore

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →